College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center and Intensive Care Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, ICU2, Mail Code 1425, PO Box 22490, Riyadh 11426, Saudi Arabia.
Section of Pulmonary and Critical Care, Medical ICU, University of Chicago, 5841 South Maryland Avenue, MC 6026, Chicago, IL 60637, USA.
Crit Care Clin. 2022 Jul;38(3):601-621. doi: 10.1016/j.ccc.2022.01.006. Epub 2022 Jan 10.
High-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) via facemask or helmet have been increasingly used in managing acute hypoxemic respiratory failure (AHRF) owing to COVID-19 with the premise of reducing the need for invasive mechanical ventilation and possibly mortality. Their use carries the risk of delaying intubation and nosocomial infection transmission. To date, most studies on the effectiveness of these modalities are observational and suggest that HFNO and NIV have a role in the management of AHRF owing to COVID-19. Trials are ongoing and are evaluating different aspects of noninvasive respiratory support in patients with AHRF owing to COVID-19.
高流量鼻氧（HFNO）和经面罩或头盔的无创通气（NIV）由于 COVID-19 导致的急性低氧性呼吸衰竭（AHRF）的管理中越来越多地被使用，前提是减少对有创机械通气的需求并可能降低死亡率。它们的使用有延迟插管和医院感染传播的风险。迄今为止，关于这些方法有效性的大多数研究都是观察性的，表明 HFNO 和 NIV 在 COVID-19 导致的 AHRF 的管理中有一定作用。试验正在进行中，正在评估 COVID-19 导致的 AHRF 患者无创呼吸支持的不同方面。
